|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
2002-1-22
|
|
pubmed:abstractText |
Although numerous clinical trials and economic analyses have established the efficacy and cost-effectiveness of lowering cholesterol for the prevention of coronary heart disease, there are few data on the role of raising high-density lipoprotein cholesterol (HDL-C) levels and lowering triglyceride levels. The US Department of Veterans Affairs (VA) Cooperative Studies Program HDL-C Intervention Trial (VA-HIT) was a multicenter, randomized trial of gemfibrozil, an agent that raised HDL-C levels and lowered triglyceride levels, yet had no effect on low-density lipoprotein cholesterol (LDL-C) levels. The study showed that gemfibrozil therapy significantly reduced major cardiovascular events (cardiovascular death, myocardial infarction, and stroke) in patients with coronary heart disease, low HDL-C levels, and low LDL-C levels.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jan
|
|
pubmed:issn |
0003-9926
|
|
pubmed:author |
pubmed-author:Bloomfield RubinsHannaH,
pubmed-author:CollinsDorotheaD,
pubmed-author:FyeCarol LCL,
pubmed-author:MartinsonMelissa SMS,
pubmed-author:NelsonDavidD,
pubmed-author:NugentSeanS,
pubmed-author:NymanJohn AJA,
pubmed-author:RobinsSander JSJ,
pubmed-author:VA-HIT Study Group,
pubmed-author:WiltTimothy JTJ,
pubmed-author:WittesJanetJ
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
28
|
|
pubmed:volume |
162
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
177-82
|
|
pubmed:dateRevised |
2010-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:11802751-Aged,
pubmed-meshheading:11802751-Cholesterol, HDL,
pubmed-meshheading:11802751-Cholesterol, LDL,
pubmed-meshheading:11802751-Coronary Artery Disease,
pubmed-meshheading:11802751-Cost-Benefit Analysis,
pubmed-meshheading:11802751-Gemfibrozil,
pubmed-meshheading:11802751-Humans,
pubmed-meshheading:11802751-Hypolipidemic Agents,
pubmed-meshheading:11802751-Male,
pubmed-meshheading:11802751-Markov Chains,
pubmed-meshheading:11802751-Middle Aged,
pubmed-meshheading:11802751-Proportional Hazards Models,
pubmed-meshheading:11802751-Quality-Adjusted Life Years,
pubmed-meshheading:11802751-Randomized Controlled Trials as Topic,
pubmed-meshheading:11802751-Triglycerides,
pubmed-meshheading:11802751-United States
|
|
pubmed:year |
2002
|
|
pubmed:articleTitle |
Cost-effectiveness of gemfibrozil for coronary heart disease patients with low levels of high-density lipoprotein cholesterol: the Department of Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial.
|
|
pubmed:affiliation |
Division of Health Services Research and Policy, University of Minnesota, 420 Delaware St SE, Mail Route 729, Minneapolis, MN 55455-0392, USA. nyman001@tc.umn.edu
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, U.S. Gov't, Non-P.H.S.,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't
|
